Cell4Pharma successfully closed a major funding round

Radboudumc spin-off Cell4Pharma is very  pleased to announced it has successfully closed a major funding round, marking a significant milestone in their journey towards developing ciPTEC as the leading platform to study human renal biological interaction during the preclinical stages of drug development.

This successful fundraising effort is a testament to the hard work and commitment of their leadership-team, as well as the confidence that investors have in their vision for the future of medical research.

With this new injection of capital, Cell4Pharma is well-positioned to accelerate the development of innovative, animal-free drug discovery platforms and bring their medicine development programs to the next level.

Cell4Pharma believes that this achievement will help to catalyze the shift towards more ethical and sustainable practices in the pharmaceutical industry, and is excited to take the next steps towards a brighter future for both patients and animals alike.

Cell4pharma envisions a world where animal experiments are obsolete. To make this a reality they are starting with eliminating renal toxicity for compounds entering clinical stages of drug development. This ambition is driven by their human renal ciPTEC cell lines and its use within their growing global network of research professionals. Cell4Pharma believes that researchers deserve the best tools available in order to deliver their best work.